New human imaging data support the neuroprotective effects of Allon’s davunetide
21-Jul-2011 -
Allon Therapeutics Inc. announced new findings that 12 weeks of treatment with the Company’s lead product davunetide appears to prevent cortical thinning of important parts of the brains of schizophrenia patients.Dr. Bruce Morimoto, Allon’s Vice-President of Drug Development, said “the new data ...
clinical trials
neurodegenerative diseases
schizophrenia